Childhood Fatty Liver Disease Drives Premature Death and Lifelong Metabolic Risk

Pediatric MASLD — the most common chronic liver disease in children — has long been underestimated as a long-term health threat. While adult studies have documented elevated mortality in MASLD patients, high-quality longitudinal data specific to children have been largely absent. The LIVERS study was designed to fill this gap by tracking a large, biopsy-confirmed pediatric cohort across decades.

Researchers at Rady Children's Hospital San Diego enrolled 1,096 children aged 2–18 years diagnosed with MASLD between 2000 and 2017. MASLD diagnosis required histologically confirmed hepatic steatosis (≥5% of hepatocytes) plus at least one cardiometabolic risk factor, consistent with updated 2023 nomenclature criteria. Liver biopsies were graded using NASH Clinical Research Network criteria. Mortality was ascertained through the National Death Index through December 31, 2018, and surviving participants were invited for prospective follow-up visits between 2019 and 2022 to assess comorbidity development.

The primary mortality findings were striking. Of the 1,096 children, 37 (3.4%) died over a mean follow-up of 8.5 years, yielding an all-cause mortality rate of 398 per 100,000 person-years. Nearly half of all deaths were liver-related — encompassing cirrhosis, hepatic encephalopathy, portal hypertension, hepatorenal syndrome, variceal hemorrhage, hepatocellular carcinoma, or liver failure. Cox proportional hazards modeling identified male sex and lower high-density lipoprotein (HDL) cholesterol as independent predictors of increased mortality risk. Standardized mortality ratios were derived using age- and sex-matched 2018 U.S. Census and California mortality data, confirming excess mortality compared to the general pediatric population.

Hepatic progression was also substantial: the cumulative incidence of cirrhosis reached 4.7%, a finding previously described largely in case reports for this age group. Extrahepatic comorbidity incidence rates were equally alarming. Dyslipidemia emerged at 3,664 per 100,000 person-years, hypertension at 1,901, obstructive sleep apnea at 1,185, and type 2 diabetes at 911. These rates underscore that pediatric MASLD is not an isolated liver condition but a systemic metabolic disease with wide-ranging organ involvement beginning in childhood.

The study's implications for clinical practice are significant. Children with MASLD — particularly males and those with low HDL — represent a high-risk population requiring aggressive early intervention, including cardiometabolic screening and long-term multidisciplinary management extending into adulthood. The findings also reinforce the public health urgency of implementing universal screening programs for at-risk children. Key limitations include the single-center design at a tertiary pediatric hospital, which may skew toward more severe disease, and the requirement for liver biopsy for enrollment, potentially underrepresenting milder cases. Nonetheless, this remains one of the largest and longest pediatric MASLD cohort studies to date.